Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Roche
Roche
Roche’s Genentech partners with Nvidia in AI drug deal
Roche’s Genentech partners with Nvidia in AI drug deal
BioPharma Dive
Roche
Genentech
artificial intelligence
NVIDIA
Flag link:
A year after Roche's Alzheimer's failure, scientists reflect on what could have been
A year after Roche's Alzheimer's failure, scientists reflect on what could have been
Fierce Biotech
Roche
Genentech
Alzheimer's disease
gantenerumab
Flag link:
European regulator endorses high-dose version of Bayer eye drug Eylea
European regulator endorses high-dose version of Bayer eye drug Eylea
Reuters
Bayer
EMA
Eylea
Roche
Flag link:
Regeneron touts launch of high-dose Eylea in battle with Roche's Vabysmo
Regeneron touts launch of high-dose Eylea in battle with Roche's Vabysmo
Fierce Pharma
Regeneron
Eylea
Roche
Vabysmo
Flag link:
Roivant’s $7B Roche deal was a ‘moment of opportunity,’ CEO says
Roivant’s $7B Roche deal was a ‘moment of opportunity,’ CEO says
BioPharma Dive
Roivant
Televant
M&A
Roche
Flag link:
Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?
Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?
Motley Fool
Roche
Eli Lilly
Pfizer
IBD
ulcerative colitis
Crohn's Disease
mirikizumab
Flag link:
FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
BioSpace
Vabysmo
Genentech
Roche
retinal vein occlusion
Flag link:
Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug
Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug
Reuters
Roche
legal
Biogen
biosimilars
Actemra
Flag link:
Roche pays $7.1B to Roivant for rights to Telavant’s IBD candidate
Roche pays $7.1B to Roivant for rights to Telavant’s IBD candidate
BioSpace
Roche
M&A
Televant
Roivant
RVT-3101
IBD
ulcerative colitis
Crohn’s disease
Flag link:
Lung Cancer Takes Center Stage at ESMO Congress 2023 With New Drugs, More Options
Lung Cancer Takes Center Stage at ESMO Congress 2023 With New Drugs, More Options
OBR Oncology
ESMO
non-small cell lung cancer
Roche
Alecensa
AstraZeneca
Tagrisso
JNJ
Rybrevant
Flag link:
Roche drops oral eye disease drug after completing phase 2, pulls back from solid tumor bispecific
Roche drops oral eye disease drug after completing phase 2, pulls back from solid tumor bispecific
Fierce Biotech
Roche
diabetic retinopathy
solid tumors
bispecific antibodies
Flag link:
Roche's Q3 sales down 3% on currency headwinds, drop in COVID sales
Roche's Q3 sales down 3% on currency headwinds, drop in COVID sales
Reuters
Roche
earnings
Vabysmo
Flag link:
Roche pays $50M upfront to Monte Rosa in molecular glue deal
Roche pays $50M upfront to Monte Rosa in molecular glue deal
Fierce Biotech
Roche
molecular glue
Monte Rosa
QuEEN
protein degradation
Flag link:
Roche builds gene therapy portfolio with SpliceBio deal
Roche builds gene therapy portfolio with SpliceBio deal
Pharmaphorum
Roche
Spark Therapeutics
SpliceBio
gene therapy
inherited retinal disease
Flag link:
Amid Eylea showdown, Roche's Vabysmo shows durability in retinal vein occlusion
Amid Eylea showdown, Roche's Vabysmo shows durability in retinal vein occlusion
Fierce Pharma
Roche
retinal vein occlusion
Vabysmo
Flag link:
Roche preps for filings after subcutaneous Ocrevus matches up to IV formulation in phase 3 study
Roche preps for filings after subcutaneous Ocrevus matches up to IV formulation in phase 3 study
Fierce Pharma
Roche
Ocrevus
MS
multiple sclerosis
clinical trials
Flag link:
Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Able to Sit Independently After 1 Year of Treatment
Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Able to Sit Independently After 1 Year of Treatment
BioSpace
Roche
Genentech
clinical trials
Evrysdi
SMA
Flag link:
Biogen nabs FDA nod for biosimilar version of Roche's blockbuster Actemra
Biogen nabs FDA nod for biosimilar version of Roche's blockbuster Actemra
Fierce Pharma
Biogen
Roche
Actemra
autoimmune disease
biosimilars
Flag link:
In label expansion bid, AbbVie and Roche's Venclexta falls short in multiple myeloma subset
In label expansion bid, AbbVie and Roche's Venclexta falls short in multiple myeloma subset
Fierce Pharma
AbbVie
Roche
Venclexta
Multiple Myeloma
Flag link:
Roche pays Ionis $60M upfront to license RNA-targeting Alzheimer's, Huntington's programs
Roche pays Ionis $60M upfront to license RNA-targeting Alzheimer's, Huntington's programs
Fierce Biotech
Roche
Ionis Pharmaceuticals
RNA
Alzheimer's disease
Huntington's disease
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »